Playback speed
10 seconds
ESMO 2024 Insights: STAMPEDE2 Trial - Stereotactic Ablative Body Radiotherapy for Newly Diagnosed Oligometastatic Prostate Cancer Starting ADT
By
2024 ESMO Annual Meeting Insights Hub
FEATURING
Hoda Abdel-Aty
By
2024 ESMO Annual Meeting Insights Hub
FEATURING
Hoda Abdel-Aty
11 views
September 24, 2024
Login to view comments.
Click here to Login